X

Drug Profile

UMN 104

Alternative Names: UMN-104

Latest Information Update: 28 Mar 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Tampere Vaccine Research Center
Developer UMN Pharma; University of Tampere Vaccine Research Center
Class Viral vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Norovirus infections

Most Recent Events

08 Mar 2023 UMN Pharma in-licenses UMN 104 from University of Tampere, Vaccine Research Center
08 Mar 2023 Early research in Norovirus infections (Prevention) in Japan (Parenteral) (UMN Pharma pipeline, March 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com